A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, ...

Soligenix, Inc. (NASDAQ: SNGX) is currently conducting the Phase 3 FLASH2 Trial of HyBryte™ (SGX301 or synthetic hypericin) in the treatment of cutaneous T cell lymphoma (CTCL). As of the latest ...

A data monitoring committee recommended stopping FLASH2, a randomized double-blind placebo-controlled confirmatory phase 3 ...

A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on ...

STOCKHOLM, Feb. 24, 2026 /PRNewswire/ -- The clinical database has been finalized for the pre-specified interim efficacy analysis in Diamyd Medical's ongoing pivotal Phase 3 trial (DIAGNODE-3) ...

Belite Bio, Inc. announced positive developments regarding its lead drug candidate, Tinlarebant, for treating Stargardt disease (STGD1) and ongoing trials for geographic atrophy (GA). Following an ...

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study At the first overall survival (OS) ...

Management expects the Phase IIb PLATEAU study to commence this quarter, targeting interim results in the first quarter of calendar year 2027. Steiner stated that the primary efficacy endpoint is ...

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy - For the primary ...

Community Cancer Centers, Including Sites New to CAR T Therapy, Accounted for Approximately 33% of Screening Activity and Cema-Cel Infusions Enrollment Expected to Complete by Year-End 2027, with an ...